Merck & Co., Inc. (MRK) Poised for 20% Gain, Analysts Say
We recently published a list of the 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts. In this article, we ...
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
FiercePharma11h
Ahead of adcomm, FDA challenges broad use of PD-1 drugs in stomach cancer patients
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
3rd Circuit Revives Fosamax MDL Over Questions of Preemption
The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...
Merck & Co Unusual Options Activity For September 23
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sutro Biopharma specializes in ADCs for oncology and shows promise with STRO-002 for ovarian cancer and collaborations with ...
kffhealthnews1d
Many Lawsuits Over Femur Risks Of Merck Drug Fosamax Can Now Proceed
More than 500 lawsuits, which a U.S. appeals court revived on Friday, allege Merck & Co. failed to warn patients that its osteoporosis drug Fosamax raised the risk of thigh bone fractures. Separately, ...
Strong Wall Street Debut Shows Potential Of Indian Billionaire-Backed Bicara’s Cancer Drugs
Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...
Challenge to US drug price negotiation program revived by appeals court
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...
Court revives more than 500 lawsuits over Fosamax femur fracture risk
A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...
Zacks.com on MSN4d
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
Claims Over Merck Osteoporosis Drug Fosamax Labeling Are Back on
A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...